Group 1 - The animal health sector experienced a significant increase of 5.61% on January 26, with Yongshun Biological leading the gains [1] - The Shanghai Composite Index closed at 4132.61, down 0.09%, while the Shenzhen Component Index closed at 14316.64, down 0.85% [1] - Key stocks in the animal health sector showed notable price increases, with Yongshun Biological rising by 27.18% to a closing price of 11.79, and Huisheng Biological increasing by 20.01% to 32.62 [1] Group 2 - The animal health sector saw a net inflow of 437 million yuan from institutional investors, while retail investors experienced a net outflow of 307 million yuan [2] - The trading volume for Yongshun Biological reached 292,600 shares, contributing to a total transaction value of 328 million yuan [1][2] - The stock performance of various companies in the sector varied, with some experiencing significant gains while others faced declines in retail investment [3]

Group 1 - The core viewpoint of the news is that Reap Bio has seen a 5% increase in stock price, reaching 21.40 CNY per share, with a trading volume of 221 million CNY and a turnover rate of 3.17%, resulting in a total market capitalization of 9.946 billion CNY [1] - Reap Bio, established on August 2, 2001, and listed on September 17, 2010, is located in the Tianjin Free Trade Zone and specializes in the research, production, sales, and technical services of veterinary biological products, chemical drugs, biological agents, and other related products [1] - The main business revenue composition of Reap Bio is 77.95% from animal protection business and 22.05% from the pet supply chain [1] Group 2 - From the perspective of the top ten circulating shareholders, Guotai Fund's ETF, Guotai Zhongzheng Animal Husbandry ETF (159865), increased its holdings by 2.3571 million shares, totaling 6.3383 million shares, which accounts for 1.89% of the circulating shares [2] - The Guotai Zhongzheng Animal Husbandry ETF has a current scale of 5.949 billion CNY, with a year-to-date loss of 0.41% and a one-year return of 15.98% [2] - The fund manager of Guotai Zhongzheng Animal Husbandry ETF, Liang Xing, has a tenure of 9 years and 235 days, with the fund's total asset size at 29.35 billion CNY and a best return of 1112.34% during the tenure [3]

Market Overview - The animal health sector experienced a decline of 0.32% on January 23, with BioShares leading the drop [1] - The Shanghai Composite Index closed at 4136.16, up 0.33%, while the Shenzhen Component Index closed at 14439.66, up 0.79% [1] Stock Performance - Notable gainers in the animal health sector included: - Qudongli (920275) with a closing price of 9.68, up 4.09% on a trading volume of 36,300 shares and a turnover of 34.72 million yuan [1] - Haili Biological (603718) closed at 6.55, up 1.24% with a trading volume of 95,100 shares and a turnover of 61.91 million yuan [1] - Deyu Biological (920970) closed at 8.44, up 1.20% with a trading volume of 19,200 shares and a turnover of 16.26 million yuan [1] - Conversely, BioShares (600201) closed at 17.35, down 1.42% with a trading volume of 315,700 shares and a turnover of 551 million yuan [2] Capital Flow - The animal health sector saw a net outflow of 142 million yuan from institutional investors, while retail investors experienced a net inflow of 124 million yuan [2][3] - Specific stock capital flows included: - Zhongmu Shares (600195) with a net inflow of 14.27 million yuan from institutional investors [3] - Qudongli (920275) had a net inflow of 2.44 million yuan from retail investors [3] - Deyu Biological (920970) faced a net outflow of 1.04 million yuan from institutional investors [3]

证券日报网讯1月22日，瑞普生物（300119）在互动平台回答投资者提问时表示，截至2026年1月20日， 公司股东总户数为25567户。 ...

Group 1 - The core viewpoint of the article is that the company, Reap Bio (300119), is committed to deepening its focus in the pet health sector and expanding its product offerings to provide more quality health solutions for pets [1] Group 2 - The company has indicated its intention to continuously enrich its product matrix in the pet health field [1] - The company aims to offer more premium health solutions for pets in the future [1]

证券日报网讯 1月22日，瑞普生物在互动平台回答投资者提问时表示，公司应收账款按与客户签订的合 同约定回款期推进回款工作，公司已严格按照账龄分析法及单项认定法计提坏账准备，相关财务处理符 合企业会计准则要求，充分考虑了回款相关风险。具体情况请关注公司后续披露的定期报告。 （文章来源：证券日报） ...

证券日报网讯1月22日，瑞普生物（300119）在互动平台回答投资者提问时表示，喵干素为重组猫干扰 素ω(冻干型)，其主要成分为重组猫干扰素ω蛋白，主要用于猫疱疹病毒感染的治疗，可提升猫咪的抗感 染能力，属于兽用生物制品。 ...

Core Viewpoint - The animal health sector experienced a slight increase of 0.54% on January 22, with Xianfeng Holdings leading the gains. The Shanghai Composite Index rose by 0.14% to close at 4122.58, while the Shenzhen Component Index increased by 0.5% to 14327.05 [1]. Group 1: Stock Performance - Xianfeng Holdings (002141) closed at 4.19, up 9.97% with a trading volume of 720,300 shares and a transaction value of 297 million yuan [1]. - Other notable performers include Biological Shares (600201) at 17.60, up 1.79%, and Zhongmu Shares (600195) at 8.54, also up 1.79% [1]. - The overall trading volume and transaction values for various stocks in the animal health sector indicate active market participation [1]. Group 2: Capital Flow - The animal health sector saw a net inflow of 73.79 million yuan from institutional investors, while retail investors experienced a net outflow of 27.83 million yuan [2]. - The main capital inflow was primarily directed towards Xianfeng Holdings, which attracted 121 million yuan from institutional investors, representing 40.71% of its trading volume [3]. - Other stocks like Jinhe Biological (002688) and *ST Green Health (002868) also saw varying degrees of net inflow and outflow from different investor categories [3].

（文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：公司年报预告什么时候公示？ 瑞普生物（300119.SZ）1月22日在投资者互动平台表示，公司2025年度报告已预约2026年3月31日披 露，相关信息请以公司后续在深交所官网、巨潮资讯网发布的正式公告为准。 ...

Group 1 - The company has launched several pet nutritional health products, including glucosamine chondroitin and squalene coenzyme Q10 [2] - In 2026, the company plans to introduce new products such as krill oil and probiotics to enhance pet health and nutrition [2] - The company aims to continue developing this sector and expand its product matrix to provide more quality health solutions for pets [2]